Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 13, 2023

BUY
$24.03 - $27.02 $187,890 - $211,269
7,819 Added 3.59%
225,485 $6.08 Million
Q3 2022

Nov 14, 2022

SELL
$11.6 - $20.44 $58,649 - $103,344
-5,056 Reduced 2.27%
217,666 $3.91 Million
Q2 2022

Aug 15, 2022

BUY
$7.78 - $14.69 $36,511 - $68,940
4,693 Added 2.15%
222,722 $2.77 Million
Q1 2022

May 13, 2022

BUY
$11.38 - $16.4 $66,777 - $96,235
5,868 Added 2.77%
218,029 $2.91 Million
Q4 2021

Feb 11, 2022

BUY
$14.31 - $23.87 $47,781 - $79,701
3,339 Added 1.6%
212,161 $3.3 Million
Q3 2021

Nov 16, 2021

BUY
$18.94 - $26.99 $303,172 - $432,028
16,007 Added 8.3%
208,822 $4.69 Million
Q2 2021

Aug 16, 2021

BUY
$17.07 - $24.56 $82,652 - $118,919
4,842 Added 2.58%
192,815 $4.39 Million
Q1 2021

May 17, 2021

BUY
$20.46 - $25.18 $3.85 Million - $4.73 Million
187,973 New
187,973 $3.87 Million

Others Institutions Holding MYOV

About Myovant Sciences Ltd.


  • Ticker MYOV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 96,802,800
  • Description
  • Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...
More about MYOV
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.